{"id":"NCT05142774","sponsor":"Organon and Co","briefTitle":"Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis","officialTitle":"An Open-Label, Long-Term Extension Study to Evaluate the Safety and Efficacy of Tapinarof Cream, 1% in Subjects With Atopic Dermatitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-10-28","primaryCompletion":"2024-02-29","completion":"2024-03-07","firstPosted":"2021-12-03","resultsPosted":"2025-08-13","lastUpdate":"2025-08-13"},"enrollment":728,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Atopic Dermatitis"],"interventions":[{"type":"DRUG","name":"Tapinarof cream, 1%","otherNames":[]}],"arms":[{"label":"tapinarof cream","type":"EXPERIMENTAL"}],"summary":"This is an open-label, long-term multicenter, study to evaluate the safety and efficacy of topical tapinarof cream, 1% in subjects with atopic dermatitis. Subjects in this study have completed treatment in one of two Phase 3 pivotal studies (DMVT-505-3101 or DMVT-505-3102) or completed treatment in the DMVT-505-2104 study, or directly enrolled into this study. This study will consist of up to 48 weeks of treatment and a 1 week safety follow-up period.","primaryOutcome":{"measure":"Number of Subjects With Treatment-Emergent Adverse Events (TEAE) and Serious Adverse Events","timeFrame":"Baseline to Week 49","effectByArm":[{"arm":"Tapinarof Cream","deltaMin":451,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":13},"locations":{"siteCount":112,"countries":["United States","Canada"]},"refs":{"pmids":["40600584"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":34,"n":728},"commonTop":["Folliculitis","Nasopharyngitis","Upper respiratory tract infection","Asthma","COVID-19"]}}